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The author replies: Gupta and Gupta point out the importance of sleep-disordered breathing in the pathobiology of adolescent hypertension, though sleep patterns were among the factors mentioned in the article as part of the medical evaluation and nonpharmacologic therapy. In ad-dition to their study, 1 work from the Tucson Children's Assessment of Sleep Apnea Study has indicated that decreased sleep time and elevated body-mass index are associated with increases in blood-pressure levels. 2 Best therapy for sleepdisordered breathing in children and adolescents is an evolving area, especially because adherence to CPAP regimens is difficult for children and adolescents, as discussed in a recent review by Tapia and Marcus. 3 Uric acid, as Bellomo notes, has been evaluated as a biomarker for essential hypertension in children and adolescents. Much data, particularly from animal models, indicate that increases in uric acid lead first to reversible vasoconstrictive changes, mediated by stimulation of renin release and a decrease in the levels of circulating nitrates, and later to a second phase in which changes in the vasculature within the kidney result in sustained blood-pressure elevation and, ultimately, to salt-sensitive hypertension. 4 Currently, short-term data indicate that the use of allopurinol in children or adolescents with hypertension may be effective, but such studies are preliminary. 4 Further and longerterm trials would be needed before allopurinol or other therapy to lower uric acid levels in children with hypertension would be recommended.
Julie R. Ingelfinger, M.D.
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Pregnancy and Infection
To the Editor: Kourtis and colleagues (June 5 issue) 1 describe the effect of pregnancy on the susceptibility to and severity of infections, but they only briefly mention the human immunodeficiency virus (HIV). This is surprising, given that HIV causes up to 25% of deaths during pregnancy and the postpartum period in women in sub-Saharan Africa. 2 Rigorous studies on the interaction between pregnancy and HIV are scarce, but most of the available data suggest that preg- nancy does not increase HIV acquisition 3 or the severity of HIV-related illness. In addition, HIV does not increase the risk of obstetrical complications, with the exception of sepsis. 4 Whether pregnancy accelerates HIV disease progression is uncertain. Pregnant women tend to have less advanced HIV disease than nonpregnant women, but few studies stratify patients according to the stage of HIV infection at the start of follow-up. A study involving HIV-infected women who were receiving antiretroviral therapy did not show that pregnancy was associated with an increased risk of death. 5 This finding implies that the HIVattributable mortality among pregnant women is largely coincidental to pregnancy, and there is little reason to discourage healthy HIV-infected women who want to become pregnant from doing so. 
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To the Editor: Kourtis et al. review specific infections in pregnancy and the available scant evidence of the increased severity of and susceptibility to infections among pregnant women. However, they omit infections caused by two important pathogens that adversely affect the health and treatment outcomes of mothers and children worldwide: Mycobacterium tuberculosis and cytomegalovirus (CMV).
Globally, tuberculosis causes an estimated half-million deaths per year in women, a large proportion of whom are of reproductive age. Although this condition remains underdiagnosed in pregnant women, the incidence of tuberculosis, tuberculosis-associated mortality, and the risk of hospitalization are high among pregnant women. 1 Clinical observations show that pregnancy may have an effect on the pathogenesis of tuberculosis and increases the maternal risk of M. tuberculosis infection or reactivation of latent tuberculosis. 2, 3 CMV infection is one of the most common viral infections in humans and can remain latent and reactivate under conditions of immunosuppression. 4 CMV infections can reactivate in pregnant women and be transmitted to the neonate in utero or through breast milk.
The complex relationships between pregnancyinduced immunologic changes and infection with intracellular pathogens remain to be defined through carefully designed case-controlled studies. 
To the Editor: The review article by Kourtis et al. focuses on the increased seriousness of a number of viral disorders, malaria, coccidioidomycosis, and a single bacterial disorder, listeriosis, during gestation. However, perhaps the most prevalent example of infection-related virulence in pregnancy is the response to severe urinary tract infection and urosepsis. An important part of prenatal care is screening to detect bacteriuria in early pregnancy, and the literature shows that asymptomatic bacteria left untreated can be followed by acute pyelonephritis in about a fourth of women in whom bacteriuria is present. 1 Moreover, as compared with complications in nonpregnant women, this infection in pregnant women can be quite virulent and can be associated with both substantial decreases in the glomerular filtration rate and volume-independent permeability pulmonary edema, which is virtually absent in nonpregnant women. 2,3 Marshall D. Lindheimer, M.D.
